Drug facts

Does tirzepatide make you tired?

Reviewed August 2026

What the label reports¹

Fatigue appears in the label’s table of adverse reactions occurring in at least 2% of treated participants and more often than on placebo, pooled from the two placebo-controlled weight-reduction trials. It is the only non-gastrointestinal reaction in that table whose rate rises at every dose step.

The placebo column is the part most pages leave out. Three percent of people who received no drug at all reported fatigue over the same period. At the highest dose the difference against placebo is four percentage points — real, and much smaller than the headline number on its own suggests.

What the label is actually counting¹

A footnote under the table defines the term. The fatigue row “includes asthenia, fatigue, lethargy, malaise” — four separate reported terms collapsed into one line. So the figure is not a count of one clearly defined experience. It is a count of four overlapping descriptions of feeling depleted, grouped for reporting.

That matters when you compare this page to another site’s. A number that appears to describe “tiredness” is describing a wider category, and the same grouping is applied to the placebo arm, so the comparison between the two columns stays valid even though the category is broad.

The label does not offer an explanation¹

There is no section of the prescribing information that proposes a mechanism for the fatigue reports. The label gives frequencies for hair loss and describes them as associated with weight reduction; it gives frequencies for fatigue and says nothing further about them at all.

Pages that explain why this drug makes people tired are not drawing on the label to do it. Where a mechanism is asserted confidently, the confidence is being supplied by the writer. How we check a claim before it goes on a page describes what we do instead when the source is silent.

Two documented risks that are not the same thing²

The label does document two conditions that a prescriber will already have in mind when a patient reports feeling drained. Neither is presented by the label as an explanation of the fatigue figure above, and neither is presented that way here.

Dehydration from gastrointestinal reactions. Section 5.3 describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, and states that the majority of reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea. Those reactions are the most common ones on the table of reactions reported in 5% or more of participants.

Hypoglycemia. Section 5.7 states that tirzepatide lowers blood glucose and can cause hypoglycemia. In the trial of participants with type 2 diabetes, hypoglycemia below 54 mg/dL was reported in 4.2% of treated participants against 1.3% on placebo, and the risk was higher again among those also taking an insulin secretagogue (10.3%) than among those who were not (2.1%).

Both are reasons to call a prescriber rather than to read further. Neither converts into a self-assessment.

Where sleep has actually been measured³

The one place tirzepatide has been studied against a sleep outcome is the SURMOUNT-OSA program: two 52-week randomized, double-blind, placebo-controlled trials in adults with moderate-to-severe obstructive sleep apnea and obesity. Its published report lists improved sleep-related patient-reported outcomes among the results, alongside reductions in the apnea-hypopnea index, body weight, hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure.

That is a finding about people who had a diagnosed sleep disorder, not about tiredness in general, and it does not speak to the fatigue percentages in the weight-reduction trials. What SURMOUNT-OSA measured, and what it deliberately did not test sets out those trials in full.

What a compounded vial changes¹

There is no comparable dataset for compounded preparations, so there is no equivalent number to print here and no placebo column to set beside it. The absence is the finding.

Where to take this⁴

To a prescriber. Fatigue is one of the least specific symptoms in medicine, and the fact that it appears on a drug label at 7% tells you nothing about why any one person is tired. If your question is about losing strength rather than energy, that is a different measurement with a different evidence base — see what the trials measured about lean mass.